HTFL insider transaction filings
Heartflow, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-21. Screen HTFL transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 25 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 19 legs across 14 filings by 3 insiders — 335,886 shares, $14,470,249 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 40.
- Largest priced transaction: sale of 35,010 shares @ $46.42 ($1,625,105) by Farquhar John C.M., filed 2026-09-14.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Farquhar John C.M. — Chief Executive Officer, Director | 9 | — | 8 legs · 198,390 sh · $7,885,624 | 8 |
| Verghese Vikram — Chief Financial Officer | 7 | — | 8 legs · 99,376 sh · $4,980,361 | 7 |
| Rogers Campbell — Chief Medical Officer | 4 | — | 3 legs · 38,120 sh · $1,604,264 | 10 |
| WELDON WILLIAM C — Director | 1 | — | — | 6 |
| BARABE TIMOTHY C — Director | 2 | — | — | 4 |
| Jones Marie L. — Chief Accounting Officer | 1 | — | — | 3 |
| Lightcap Jeffrey C — Director | 1 | — | — | 2 |
Recent Form 4 filings — Heartflow, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-21 | 4 | Rogers Campbell — Chief Medical Officer | Option exercise (M): 12,329 @ $8.33 · Option exercise (M): 850 @ $2.22 · Sale (S): 19,682 @ $50.15 · Option exercise (M): 12,329 (derivative) @ $0 · Option exercise (M): 850 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Verghese Vikram — Chief Financial Officer | Sale (S): 7,579 @ $50.11 · Sale (S): 16,766 @ $50.75 | EDGAR |
| 2026-09-15 | 4 | Verghese Vikram — Chief Financial Officer | Sale (S): 29,714 @ $50.06 · Sale (S): 4,593 @ $50.24 · Sale (S): 668 @ $50.01 | EDGAR |
| 2026-09-14 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 35,010 @ $46.42 · Sale (S): 3,890 @ $50 | EDGAR |
| 2026-09-10 | 4 | Verghese Vikram — Chief Financial Officer | Sale (S): 6,640 @ $50.03 | EDGAR |
| 2026-09-04 | 4 | Verghese Vikram — Chief Financial Officer | Sale (S): 5,876 @ $50.60 · Sale (S): 27,540 @ $49.69 | EDGAR |
| 2026-08-25 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 27,230 @ $50 | EDGAR |
| 2026-08-20 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 32,676 @ $45 | EDGAR |
| 2026-08-19 | 4 | Rogers Campbell — Chief Medical Officer | Option exercise (M): 9,219 @ $19 · Sale (S): 9,219 @ $41.23 · Option exercise (M): 9,219 (derivative) @ $0 | EDGAR |
| 2026-08-18 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 15,560 @ $39.06 | EDGAR |
| 2026-08-12 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 22,562 @ $28.31 | EDGAR |
| 2026-08-10 | 4 | Jones Marie L. — Chief Accounting Officer | Grant/award (A): 1,661 @ $16.15 · Tax withholding (F): 486 @ $27.19 · Tax withholding (F): 82 @ $28.82 | EDGAR |
| 2026-08-10 | 4 | Verghese Vikram — Chief Financial Officer | Grant/award (A): 671 @ $16.15 · Tax withholding (F): 1,537 @ $27.19 · Tax withholding (F): 473 @ $28.82 | EDGAR |
| 2026-08-10 | 4 | Rogers Campbell — Chief Medical Officer | Tax withholding (F): 1,635 @ $27.19 · Tax withholding (F): 637 @ $28.82 | EDGAR |
| 2026-08-10 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Tax withholding (F): 5,847 @ $27.19 · Tax withholding (F): 1,904 @ $28.82 | EDGAR |
| 2026-07-31 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Option exercise (M): 2,789 @ $8.33 · Option exercise (M): 18,694 @ $2.22 · Option exercise (M): 9,737 @ $9.58 · Option exercise (M): 18,694 (derivative) @ $0 · Option exercise (M): 2,789 (derivative) @ $0 · Option exercise (M): 9,737 (derivative) @ $0 | EDGAR |
| 2026-07-28 | 4 | Verghese Vikram — Chief Financial Officer | Option exercise (M): 22,522 @ $2.22 · Option exercise (M): 22,522 (derivative) @ $0 | EDGAR |
| 2026-07-28 | 4 | Lightcap Jeffrey C — Director | Option exercise (M): 47,420 @ $19 · Option exercise (M): 47,420 (derivative) @ $0 | EDGAR |
| 2026-07-24 | 4 | BARABE TIMOTHY C — Director | Option exercise (M): 3,710 @ $19 · Option exercise (M): 3,710 (derivative) @ $0 | EDGAR |
| 2026-07-23 | 4 | Verghese Vikram — Chief Financial Officer | Option exercise (M): 22,522 @ $2.22 · Option exercise (M): 22,522 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | BARABE TIMOTHY C — Director | Option exercise (M): 5,000 @ $19 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | Rogers Campbell — Chief Medical Officer | Option exercise (M): 9,219 @ $19 · Sale (S): 9,219 @ $25.72 · Option exercise (M): 9,219 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 22,562 @ $27.75 | EDGAR |
| 2026-07-10 | 4 | WELDON WILLIAM C — Director | Option exercise (M): 17,123 @ $8.33 · Option exercise (M): 17,123 @ $8.33 · Option exercise (M): 17,123 @ $8.33 · Option exercise (M): 17,123 (derivative) @ $0 · Option exercise (M): 17,123 (derivative) @ $0 · Option exercise (M): 17,123 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 38,900 @ $35 | EDGAR |
| 2026-06-18 | 4 | Cullivan Julie A — Director | Grant/award (A): 16,075 (derivative) @ $32.05 | EDGAR |
| 2026-06-18 | 4 | Lightcap Jeffrey C — Director | Grant/award (A): 16,075 (derivative) @ $32.05 | EDGAR |
| 2026-06-18 | 4 | Tansey Casey M — Director | Grant/award (A): 16,075 (derivative) @ $32.05 | EDGAR |
| 2026-06-18 | 4 | Riley Wayne Joseph — Director | Grant/award (A): 16,075 (derivative) @ $32.05 | EDGAR |
| 2026-06-18 | 4 | BARABE TIMOTHY C — Director | Grant/award (A): 16,075 (derivative) @ $32.05 | EDGAR |
| 2026-06-18 | 4 | WELDON WILLIAM C — Director | Grant/award (A): 16,075 (derivative) @ $32.05 | EDGAR |
| 2026-06-17 | 4 | Rogers Campbell — Chief Medical Officer | Option exercise (M): 10,000 @ $2.22 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 22,562 @ $28.50 | EDGAR |
| 2026-05-20 | 4 | Rogers Campbell — Chief Medical Officer | Option exercise (M): 9,219 @ $19 · Sale (S): 9,219 @ $28.34 · Option exercise (M): 9,219 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 22,562 @ $29.12 | EDGAR |
| 2026-05-08 | 4 | Jones Marie L. — Chief Accounting Officer | Tax withholding (F): 485 @ $30.29 · Tax withholding (F): 82 @ $29.98 | EDGAR |
| 2026-05-08 | 4 | Rogers Campbell — Chief Medical Officer | Tax withholding (F): 1,634 @ $30.29 · Tax withholding (F): 637 @ $29.98 | EDGAR |
| 2026-05-08 | 4 | Verghese Vikram — Chief Financial Officer | Tax withholding (F): 1,536 @ $30.29 · Tax withholding (F): 473 @ $29.98 | EDGAR |
| 2026-05-08 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Tax withholding (F): 5,300 @ $30.29 · Tax withholding (F): 1,904 @ $29.98 | EDGAR |
| 2026-04-30 | 4 | Bain Capital Life Sciences Investors, LLC — 10% owner Bain Capital Life Sciences III General Partner, LLC — 10% owner Bain Capital Life Sciences Fund III, L.P. — 10% owner BCLS Fund III Investments GP, LLC — 10% owner BCLS Fund III Investments, LP — 10% owner | Sale (S): 254,110 @ $30.51 · Sale (S): 797,133 @ $29.37 · Sale (S): 892,533 @ $29.18 · Sale (S): 56,224 @ $30.05 | EDGAR |
| 2026-04-14 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 22,562 @ $26.72 | EDGAR |
| 2026-04-03 | 4 | Rogers Campbell — Chief Medical Officer | Option exercise (M): 291 @ $8.33 · Option exercise (M): 19,111 @ $2.22 · Option exercise (M): 40,766 @ $2.22 · Option exercise (M): 6,849 @ $2.22 · Sale (S): 64,533 @ $24.64 · Option exercise (M): 6,849 (derivative) @ $0 · +3 more | EDGAR |
| 2026-03-26 | 4 | HealthCor Partners Management LP — Director | Other (J): 4,615,542 | EDGAR |
| 2026-03-26 | 4 | Lightcap Jeffrey C — Director | Other (J): 206,261 @ $0 | EDGAR |
| 2026-03-23 | 4 | Rogers Campbell — Chief Medical Officer | Option exercise (M): 19,402 @ $2.22 · Option exercise (M): 47,615 @ $2.22 · Sale (S): 64,533 @ $25.69 · Option exercise (M): 19,402 (derivative) @ $0 · Option exercise (M): 47,615 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Sale (S): 9,725 @ $25 | EDGAR |
| 2026-03-12 | 4 | Farquhar John C.M. — Chief Executive Officer, Director | Grant/award (A): 2,631 @ $16.15 · Sale (S): 12,837 @ $22.66 | EDGAR |
| 2026-03-12 | 4 | BARABE TIMOTHY C — Director | Option exercise (M): 8,667 @ $2.22 · Option exercise (M): 8,667 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Cullivan Julie A — Director | Sale (S): 9,122 @ $25 | EDGAR |
| 2026-02-19 | 4 | BARABE TIMOTHY C — Director | Option exercise (M): 2,497 @ $8.33 · Option exercise (M): 2,497 (derivative) @ $0 | EDGAR |
Recent 8-K events — Heartflow, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-18 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure | EDGAR |
| 2025-08-25 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2025-08-11 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=HTFL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →